HK1045646A1 - Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof - Google Patents
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereofInfo
- Publication number
- HK1045646A1 HK1045646A1 HK02105870.2A HK02105870A HK1045646A1 HK 1045646 A1 HK1045646 A1 HK 1045646A1 HK 02105870 A HK02105870 A HK 02105870A HK 1045646 A1 HK1045646 A1 HK 1045646A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- preparation
- active agents
- pharmacologically active
- protein stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/316,642 US6749868B1 (en) | 1993-02-22 | 1999-05-21 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
PCT/US2000/013954 WO2000071079A2 (en) | 1999-05-21 | 2000-05-19 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1045646A1 true HK1045646A1 (en) | 2002-12-06 |
Family
ID=23229970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02105870.2A HK1045646A1 (en) | 1999-05-21 | 2002-08-12 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1178786A4 (en) |
AU (3) | AU784416B2 (en) |
CA (2) | CA2371912C (en) |
HK (1) | HK1045646A1 (en) |
WO (1) | WO2000071079A2 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
BR0015149A (en) * | 1999-10-27 | 2002-10-29 | Baker Norton Pharma | Method and compositions for administering taxanes orally to human patients |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
BR0212833A (en) | 2001-09-26 | 2004-10-13 | Baxter Int | Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
WO2003032906A2 (en) * | 2001-10-15 | 2003-04-24 | Crititech, Inc. | Delivery of poorly soluble drugs |
ITMI20020680A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
NZ518997A (en) * | 2002-05-16 | 2004-12-24 | Interag | Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent |
SI21222A (en) * | 2002-05-28 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Method for preparation of nanoparticles |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
EP3470084A1 (en) | 2002-12-09 | 2019-04-17 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
CN101102740A (en) * | 2005-01-07 | 2008-01-09 | 卫材R&D管理有限公司 | Medicinal composition and process for producing the same |
PT1853250E (en) | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20060280786A1 (en) * | 2005-06-14 | 2006-12-14 | Rabinow Barrett E | Pharmaceutical formulations for minimizing drug-drug interactions |
CN104189905A (en) | 2005-08-31 | 2014-12-10 | 阿布拉科斯生物科学有限公司 | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
US20100166872A1 (en) * | 2005-10-21 | 2010-07-01 | Amarjit Singh | Novel improved compositions for cancer therapy |
JP5301995B2 (en) * | 2006-08-29 | 2013-09-25 | 富士フイルム株式会社 | Hydrophilic matrix encapsulating poorly water-soluble compounds and process |
JP5933893B2 (en) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス, エルエルシー | Breast cancer therapy using nanoparticles containing taxanes based on hormone receptor status |
UA118645C2 (en) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | METHOD OF COMBINED CANCER THERAPY OF NANOPARTICLES CONTAINING RAPAMYCINE AND ALBUMIN |
CA2689914C (en) | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
FR2924024B1 (en) | 2007-11-27 | 2012-08-17 | Centre Nat Rech Scient | NANOPARTICLES OF THERAPEUTIC ACTIVE INGREDIENTS OF LOW AQUEOUS SOLUBILITY |
KR20100048751A (en) * | 2008-10-31 | 2010-05-11 | 주식회사 동성바이오레인 | Capsulated functional dual core aerosol composition and the method for their manufacture |
EP2370060B1 (en) | 2008-11-27 | 2017-05-03 | B.R.A.I.N. Biotechnology Research and Information Network AG | Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations |
CN102317315A (en) | 2009-02-11 | 2012-01-11 | 诺维信生物制药丹麦公司 | Albumin variants and conjugates |
JP5781500B2 (en) | 2009-04-15 | 2015-09-24 | アブラクシス バイオサイエンス, エルエルシー | Nanoparticle compositions and methods without prions |
CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
ES2580135T3 (en) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
CN107158389A (en) | 2010-03-29 | 2017-09-15 | 阿布拉科斯生物科学有限公司 | Strengthen the method for medicine delivery and therapeutic agent validity |
NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
AU2011261685B2 (en) | 2010-06-04 | 2016-02-11 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
RU2019134053A (en) | 2011-12-14 | 2019-12-11 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | APPLICATION OF POLYMERIC EXCIPIENTS FOR LYOFILIZATION OR FREEZING OF PARTICLES |
PL2825556T3 (en) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Albumin variants |
JP6487328B2 (en) | 2012-11-08 | 2019-03-20 | アルブミディクス リミティド | Albumin variant |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
PT106738B (en) * | 2013-01-09 | 2015-06-08 | Hovione Farmaciencia Sa | METHOD FOR THE CONTROL OF OSTWALD DIFUSIONAL DEGRADATION PHENOMENON (OSTWALD RIPENING) IN THE PROCESSING OF PARTICLES OF A PHARMACEUTICAL INGREDIENT |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
CN105228612A (en) | 2013-03-12 | 2016-01-06 | 阿布拉科斯生物科学有限公司 | The method for the treatment of pulmonary carcinoma |
RU2015143490A (en) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | METHODS FOR TREATING BLADDER CANCER |
CN104548116A (en) * | 2013-10-11 | 2015-04-29 | 程树海 | Preparation method of stable protein drug-loaded microparticle system |
CN104434808A (en) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术(石家庄)有限公司 | Therapeutic nanoparticles and preparation method thereof |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
KR20230165356A (en) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treating epithelioid cell tumors |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
DE102016125666A1 (en) * | 2016-12-23 | 2018-06-28 | Michael Denck | HSA Galenik |
CN110753541A (en) * | 2017-04-24 | 2020-02-04 | Zy治疗公司 | Pharmaceutical compositions for in vivo delivery, process for preparing substantially water insoluble pharmacologically active agents |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
CN115003284A (en) | 2019-10-28 | 2022-09-02 | 阿布拉科斯生物科学有限公司 | Pharmaceutical composition of albumin and rapamycin |
US20230025865A1 (en) * | 2019-12-11 | 2023-01-26 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
CN100462066C (en) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof |
-
2000
- 2000-05-19 EP EP00932669A patent/EP1178786A4/en not_active Ceased
- 2000-05-19 AU AU50359/00A patent/AU784416B2/en not_active Expired
- 2000-05-19 CA CA2371912A patent/CA2371912C/en not_active Expired - Lifetime
- 2000-05-19 WO PCT/US2000/013954 patent/WO2000071079A2/en active IP Right Grant
- 2000-05-19 CA CA2684454A patent/CA2684454A1/en not_active Abandoned
-
2002
- 2002-08-12 HK HK02105870.2A patent/HK1045646A1/en unknown
-
2006
- 2006-06-30 AU AU2006202836A patent/AU2006202836B2/en not_active Expired
-
2009
- 2009-09-21 AU AU2009217409A patent/AU2009217409A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000071079A3 (en) | 2008-03-27 |
AU784416B2 (en) | 2006-03-30 |
EP1178786A1 (en) | 2002-02-13 |
AU2006202836A1 (en) | 2006-07-27 |
AU5035900A (en) | 2000-12-12 |
AU2009217409A1 (en) | 2009-10-08 |
AU2006202836B2 (en) | 2009-10-08 |
EP1178786A4 (en) | 2006-03-01 |
WO2000071079A2 (en) | 2000-11-30 |
CA2684454A1 (en) | 2000-11-18 |
CA2371912A1 (en) | 2000-11-30 |
CA2371912C (en) | 2010-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1045646A1 (en) | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | |
HK1050367A1 (en) | Pharmaceutically active compounds. | |
IL137346A0 (en) | Pharmaceutically active morpholinol | |
HK1048999A1 (en) | Azepinoindole derivatives, their preparation and use thereof | |
HUP0402113A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof | |
ZA200201509B (en) | Pharmaceutically active sulfonamide derivatives. | |
HK1040398A1 (en) | Pyridopyranoazepine derivatives, preparation and therapeutic use | |
HUP0105039A3 (en) | Fungicidal propargylether derivatives, preparation and use thereof | |
ZA200007415B (en) | Amino acid derivatives and drugs containing the same as the active ingredient. | |
HK1031725A1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | |
EP1210084A4 (en) | Pyridomorphinans, thienomoprhinans and use thereof | |
HRP20040171A2 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
AU2662799A (en) | Modified pharmacologically active agents and improved therapeutic methods employing same | |
HUP0202377A3 (en) | N-substituted perhydrodiazines, preparation and use thereof | |
ZA200110046B (en) | Therapeutic agents. | |
EP1234834A4 (en) | 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | |
SI1043306T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | |
AU2001262699A1 (en) | Biologically active agents and drugs | |
ZA989312B (en) | Novel pharmaceutically active compounds, their preparation and use. | |
HUP0203678A3 (en) | Nitro-sulfobenzamide-derivatives, preparation and use thereof | |
HUP0203455A3 (en) | 2-arylquinoline derivatives, preparation and therautic use thereof | |
IL150237A0 (en) | Benzophenone glycopyranosides, preparation and therapeutic use | |
AUPP899699A0 (en) | Peptides, agents and methods | |
GB9801230D0 (en) | Pharmaceutically active morpholinol | |
IL158978A0 (en) | Pharmaceutically active morpholinol |